Table 5.
Recruiting trials in the second or further lines for advanced urothelial carcinoma.
| Study name/ID | Investigational drug | Phase | Primary end point |
|---|---|---|---|
| TROPiCS-04 (Clinicaltrial.gov identifier: NCT04527991) | Sacituzumab govitecan | III | OS |
| NCT03448718 | Olaparib | II | ORR |
| NCT04383067 | Adoptative cell therapy | II | OTR |
| NCT03513952 | Atezolizumab + recombinant human IL-7 | II | ORR |
| NCT03557918 | Tremelimumab | II | ORR |
| NCT03547973 | Sacituzumab govitecan | II | ORR |
| CabUC NCT04066595 | Cabozantinib | II | ORR |
| NCT03676946 | ZKAB001 (PD-L1 antibody) | I/II | DLT |
| NCT04562311 | Chidamide + immunotherapy | II | ORR |
| NCT03854474 | Tazemetostat | I/II | ORR |
| NCT03744793 | Pemetrexede + avelumab | II | ORR |
| NCT04073602 | Recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate | II | ORR |
| AVETAX-NCT03575013 | Avelumab + taxane | Ib | DLT/ORR |
| NCT03915405 | KHK2455 (IDO inhibitor) + avelumab | I | TRAE |
| NCT03606174 | Sitravatinib + immunotherapy | II | ORR |
| NCT02717156 | sEphB4-HAS + pembrolizumab | II | TRAE/ORR |
| NCT03375307 | NCT03375307 | II | ORR |
| NCT04045613 | Derazantinib + atezolizumab | Ib/II | ORR/recommended phase II dose |
| NCT04349280 | Bintrafusp Alfa | IB | ORR |
| NCT04492293 | ICP-192 (FGFR inhibitor) | II | ORR |
| NCT03473743 | Erdafinitib + cetrelimab | I/II | DLT/ORR/TRAE |
| NCT03606174 | Sitravatinib + PD-(L)1 inhibitor | II | ORR |
DLT, dose limiting toxicity; OTR, objective tumor response; ORR, objective response rate; TRAE, treatment related adverse event.